{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T03:34:43Z","timestamp":1764905683470},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Invasive meningococcal disease (IMD) is a global health problem and vaccination has proven the most effective way of disease control. <jats:italic>Neisseria meningitidis<\/jats:italic> serogroup X (<jats:italic>Nm<\/jats:italic>X) is an emerging threat in the African sub-Saharan meningitis belt, but no vaccine is available today. Leading vaccines against <jats:italic>Nm<\/jats:italic> are glycoconjugates, in which capsular polysaccharides isolated from large-scale pathogen cultures are conjugated to adjuvant proteins. Though safe and efficacious even in infants, high costs and biohazard associated with the production limit abundant application of glycoconjugate vaccines particularly in the most afflicted nations. An existing <jats:italic>Nm<\/jats:italic>X vaccine candidate (CPSXn-CRM<jats:sub>197<\/jats:sub>) produced by established protocols from <jats:italic>Nm<\/jats:italic>X capsule polysaccharide (CPSX) has been shown to elicit high bactericidal immunoglobulin G titres in mice. Here we describe the scalable <jats:italic>in vitro<\/jats:italic> synthesis of CPSXiv from chemically pure precursors by the use of recombinant <jats:italic>Nm<\/jats:italic>X capsule polymerase. Application of the described coupling chemistry gives CPSXiv-CRM<jats:sub>197<\/jats:sub>, which in mouse vaccination experiments behaves identical to the benchmark CPSXn-CRM<jats:sub>197<\/jats:sub>. Excluding any biohazards, this novel process represents a paradigm shift in vaccine production and a premise towards vaccine manufacturing in emerging economies.<\/jats:p>","DOI":"10.1038\/npjvaccines.2016.17","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T19:07:22Z","timestamp":1479236842000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["An efficient cell free enzyme-based total synthesis of a meningococcal vaccine candidate"],"prefix":"10.1038","volume":"1","author":[{"given":"Timm","family":"Fiebig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosaria","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Oldrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Tontini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Brogioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Berti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Gerardy-Schahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,15]]},"reference":[{"issue":"Suppl 2","key":"BFnpjvaccines201617_CR1","doi-asserted-by":"publisher","first-page":"B71","DOI":"10.1016\/j.vaccine.2009.04.070","volume":"27","author":"D Stephens","year":"2009","unstructured":"Stephens, D. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 27 (Suppl 2): B71\u2013B77 (2009).","journal-title":"Vaccine"},{"key":"BFnpjvaccines201617_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3201\/eid2102.141037","volume":"21","author":"MP Broderick","year":"2015","unstructured":"Broderick, M. P., Phillips, C. & Faix, D. Meningococcal disease in US military personnel before and after adoption of conjugate vaccine. Emerg. Infect. Dis. 21, 377\u2013379 (2015).","journal-title":"Emerg. Infect. Dis."},{"key":"BFnpjvaccines201617_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1042\/CS20090513","volume":"118","author":"DJ Hill","year":"2010","unstructured":"Hill, D. J., Griffiths, N. J., Borodina, E. & Virji, M. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin. Sci. (Lond) 118, 547\u2013564 (2010).","journal-title":"Clin. Sci. (Lond)"},{"key":"BFnpjvaccines201617_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3201\/eid2108.141837","volume":"21","author":"MM Kratz","year":"2015","unstructured":"Kratz, M. M. et al. Community-Based Outbreak of Neisseria meningitidis Serogroup C Infection in Men who Have Sex with Men, New York City, New York, USA, 2010-2013. Emerg. Infect. Dis. 21, 1379\u20131386 (2015).","journal-title":"Emerg. Infect. Dis."},{"key":"BFnpjvaccines201617_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1126\/science.341.6144.328","volume":"341","author":"K Kupferschmidt","year":"2013","unstructured":"Kupferschmidt, K. Infectious diseases. Bacterial meningitis finds new niche in gay communities. Science 341, 328 (2013).","journal-title":"Science"},{"key":"BFnpjvaccines201617_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.micpath.2013.02.003","volume":"57","author":"NM Caesar","year":"2013","unstructured":"Caesar, N. M., Myers, K. A. & Fan, X. Neisseria meningitidis serogroup B vaccine development. Microb. Pathog. 57, 33\u201340 (2013).","journal-title":"Microb. Pathog."},{"key":"BFnpjvaccines201617_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0163-4453(97)80004-7","volume":"34","author":"KA Cartwright","year":"1997","unstructured":"Cartwright, K. A. & Ala\u2019Aldeen, D. A. Neisseria meningitidis: clinical aspects. J. Infect. 34, 15\u201319 (1997).","journal-title":"J. Infect."},{"key":"BFnpjvaccines201617_CR8","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMra0906357","volume":"362","author":"LK Tan","year":"2010","unstructured":"Tan, L. K., Carlone, G. M. & Borrow, R. Advances in the development of vaccines against Neisseria meningitidis. N. Engl. J. Med. 362, 1511\u20131520 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnpjvaccines201617_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/archdischild-2012-302036","volume":"97","author":"S Nadel","year":"2012","unstructured":"Nadel, S. Prospects for eradication of meningococcal disease. Arch. Dis. Child 97, 993\u2013998 (2012).","journal-title":"Arch. Dis. Child"},{"key":"BFnpjvaccines201617_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1517\/17460441.2011.609554","volume":"6","author":"P Costantino","year":"2011","unstructured":"Costantino, P., Rappuoli, R. & Berti, F. The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opin. Drug Discov 6, 1045\u20131066 (2011).","journal-title":"Expert Opin. Drug Discov"},{"issue":"Suppl 5","key":"BFnpjvaccines201617_CR11","doi-asserted-by":"publisher","first-page":"S396","DOI":"10.1093\/cid\/civ594","volume":"61","author":"K Tiffay","year":"2015","unstructured":"Tiffay, K., Jodar, L., Kieny, M. P., Socquet, M. & Laforce, F. M. The Evolution of the Meningitis Vaccine Project. Clin. Infect. Dis. 61 (Suppl 5): S396\u2013S403 (2015).","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 1","key":"BFnpjvaccines201617_CR12","doi-asserted-by":"publisher","first-page":"A97","DOI":"10.1016\/j.vaccine.2007.04.049","volume":"25","author":"FM Laforce","year":"2007","unstructured":"Laforce, F. M., Konde, K., Viviani, S. & Preziosi, M. P. The Meningitis Vaccine Project. Vaccine 25 (Suppl 1): A97\u2013A100 (2007).","journal-title":"Vaccine"},{"key":"BFnpjvaccines201617_CR13","first-page":"759","volume":"42","author":"YL Tzeng","year":"2015","unstructured":"Tzeng, Y. L., Thomas, J. & Stephens, D. S. Regulation of capsule in Neisseria meningitidis. Crit Rev. Microbiol. 42, 759\u2013772 (2015).","journal-title":"Crit Rev. Microbiol."},{"key":"BFnpjvaccines201617_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S1473-3099(09)70132-X","volume":"9","author":"H Lo","year":"2009","unstructured":"Lo, H., Tang, C. M. & Exley, R. M. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect. Dis. 9, 418\u2013427 (2009).","journal-title":"Lancet Infect. Dis."},{"key":"BFnpjvaccines201617_CR15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/373715a0","volume":"373","author":"M Eckhardt","year":"1995","unstructured":"Eckhardt, M. et al. Molecular characterization of eukaryotic polysialyltransferase-1. Nature 373, 715\u2013718 (1995).","journal-title":"Nature"},{"key":"BFnpjvaccines201617_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1517\/14712598.2012.725718","volume":"13","author":"D Pace","year":"2013","unstructured":"Pace, D. Glycoconjugate vaccines. Expert Opin. Biol. Ther. 13, 11\u201333 (2013).","journal-title":"Expert Opin. Biol. Ther."},{"key":"BFnpjvaccines201617_CR17","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1016\/j.vaccine.2013.04.036","volume":"31","author":"O Xie","year":"2013","unstructured":"Xie, O., Pollard, A. J., Mueller, J. E. & Norheim, G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 31, 2852\u20132861 (2013).","journal-title":"Vaccine"},{"key":"BFnpjvaccines201617_CR18","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/S0140-6736(15)61050-9","volume":"385","author":"J Maurice","year":"2015","unstructured":"Maurice, J. Vaccine shortage threatens spread of meningitis in Niger. Lancet 385, 2241 (2015).","journal-title":"Lancet"},{"key":"BFnpjvaccines201617_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/glycob\/cwt102","volume":"24","author":"T Fiebig","year":"2014","unstructured":"Fiebig, T. et al. Functional expression of the capsule polymerase of Neisseria meningitidis serogroup X: a new perspective for vaccine development. Glycobiology 24, 150\u2013158 (2014).","journal-title":"Glycobiology"},{"key":"BFnpjvaccines201617_CR20","doi-asserted-by":"publisher","first-page":"19395","DOI":"10.1074\/jbc.M114.575142","volume":"289","author":"T Fiebig","year":"2014","unstructured":"Fiebig, T. et al. Molecular cloning and functional characterization of components of the capsule biosynthesis complex of Neisseria meningitidis serogroup A: toward in vitro vaccine production. J. Biol. Chem. 289, 19395\u201319407 (2014).","journal-title":"J. Biol. Chem."},{"key":"BFnpjvaccines201617_CR21","doi-asserted-by":"publisher","first-page":"19077","DOI":"10.1073\/pnas.1314476110","volume":"110","author":"F Micoli","year":"2013","unstructured":"Micoli, F. et al. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc. Natl Acad. Sci. USA 110, 19077\u201319082 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnpjvaccines201617_CR22","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1016\/j.vaccine.2012.08.021","volume":"30","author":"F Berti","year":"2012","unstructured":"Berti, F. et al. Relative stability of meningococcal serogroup A and X polysaccharides. Vaccine 30, 6409\u20136415 (2012).","journal-title":"Vaccine"},{"key":"BFnpjvaccines201617_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","volume":"39","author":"M Br\u00f6ker","year":"2011","unstructured":"Br\u00f6ker, M., Costantino, P., DeTora, L., McIntosh, E. D. & Rappuoli, R. Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals 39, 195\u2013204 (2011).","journal-title":"Biologicals"},{"key":"BFnpjvaccines201617_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ab.2013.08.001","volume":"442","author":"F Micoli","year":"2013","unstructured":"Micoli, F. et al. Meningococcal X polysaccharide quantification by high-performance anion-exchange chromatography using synthetic N-acetylglucosamine-4-phosphate as standard. Anal. Biochem. 442, 259\u2013261 (2013).","journal-title":"Anal. Biochem."},{"key":"BFnpjvaccines201617_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1086\/511646","volume":"44","author":"P Boisier","year":"2007","unstructured":"Boisier, P. et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis. 44, 657\u2013663 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"BFnpjvaccines201617_CR26","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/00029330-200804010-00017","volume":"121","author":"C Chen","year":"2008","unstructured":"Chen, C. et al. A first meningococcal meningitis case caused by serogroup X Neisseria meningitidis strains in China. Chin. Med. J. (Engl. ) 121, 664\u2013666 (2008).","journal-title":"Chin. Med. J. (Engl. )"},{"key":"BFnpjvaccines201617_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3201\/eid1602.091553","volume":"16","author":"C Fazio","year":"2010","unstructured":"Fazio, C. et al. Neisseria meningitidis serogroup X sequence type 2888, Italy. Emerg. Infect. Dis. 16, 359\u2013360 (2010).","journal-title":"Emerg. Infect. Dis."},{"key":"BFnpjvaccines201617_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jinf.2011.11.009","volume":"64","author":"D Vicente","year":"2012","unstructured":"Vicente, D., Esnal, O. & Perez-Trallero, E. Fatal Neisseria meningitidis serogroup X sepsis in immunocompromised patients in Spain. Virulence of clinical isolates. J. Infect. 64, 184\u2013187 (2012).","journal-title":"J. Infect."},{"key":"BFnpjvaccines201617_CR29","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1128\/JCM.01417-10","volume":"48","author":"A Kilic","year":"2010","unstructured":"Kilic, A. et al. Neisseria meningitidis serogroup X sequence type 767 in Turkey. J. Clin. Microbiol. 48, 4340\u20134341 (2010).","journal-title":"J. Clin. Microbiol."},{"key":"BFnpjvaccines201617_CR30","doi-asserted-by":"publisher","first-page":"e19513","DOI":"10.1371\/journal.pone.0019513","volume":"6","author":"I Delrieu","year":"2011","unstructured":"Delrieu, I. et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 6, e19513 (2011).","journal-title":"PLoS One"},{"key":"BFnpjvaccines201617_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.4269\/ajtmh.2009.80.619","volume":"80","author":"DM Mutonga","year":"2009","unstructured":"Mutonga, D. M. et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Am. J. Trop. Med. Hyg. 80, 619\u2013624 (2009).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"BFnpjvaccines201617_CR32","doi-asserted-by":"publisher","first-page":"12307","DOI":"10.1073\/pnas.1400473111","volume":"111","author":"CA MacLennan","year":"2014","unstructured":"MacLennan, C. A. & Saul, A. Vaccines against poverty. Proc. Natl Acad. Sci. USA 111, 12307\u201312312 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnpjvaccines201617_CR33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1377\/hlthaff.2015.1418","volume":"35","author":"AK Shen","year":"2016","unstructured":"Shen, A. K. et al. Country ownership and Gavi transition: comprehensive approaches to supporting new vaccine introduction. Health Aff. (Millwood) 35, 272\u2013276 (2016).","journal-title":"Health Aff. (Millwood)"},{"key":"BFnpjvaccines201617_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/526165a","volume":"526","author":"S Berkley","year":"2015","unstructured":"Berkley, S. Make vaccine coverage a key UN health indicator. Nature 526, 165 (2015).","journal-title":"Nature"},{"key":"BFnpjvaccines201617_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-1-4939-2874-3_14","volume":"1331","author":"C Jones","year":"2015","unstructured":"Jones, C. Glycoconjugate vaccines: the regulatory framework. Methods Mol. Biol. 1331, 229\u2013251 (2015).","journal-title":"Methods Mol. Biol."},{"key":"BFnpjvaccines201617_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.biologicals.2013.12.001","volume":"42","author":"SR Chilukuri","year":"2014","unstructured":"Chilukuri, S. R. et al. Process development and immunogenicity studies on a serogroup \u2018X\u2019 Meningococcal polysaccharide conjugate vaccine. Biologicals 42, 160\u2013168 (2014).","journal-title":"Biologicals"},{"key":"BFnpjvaccines201617_CR37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1128\/iai.1.1.8-14.1970","volume":"1","author":"JA Robinson","year":"1970","unstructured":"Robinson, J. A. & Apicella, M. A. Isolation and characterization of Neisseria meningitidis Groups A, C, X and Y polysaccharide antigens. Infect. Immun. 1, 8\u201314 (1970).","journal-title":"Infect. Immun."},{"key":"BFnpjvaccines201617_CR38","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1016\/S0021-9258(19)42390-9","volume":"249","author":"DR Bundle","year":"1974","unstructured":"Bundle, D. R., Jennings, H. J. & Kenny, C. P. Studies on the group-specific polysaccharide of Neisseria meningitidis serogroup X and an improved procedure for its isolation. J. Biol. Chem. 249, 4797\u20134801 (1974).","journal-title":"J. Biol. Chem."},{"key":"BFnpjvaccines201617_CR39","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1016\/j.vaccine.2012.07.032","volume":"30","author":"O Xie","year":"2012","unstructured":"Xie, O. et al. Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies. Vaccine 30, 5812\u20135823 (2012).","journal-title":"Vaccine"},{"key":"BFnpjvaccines201617_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ab.2012.04.033","volume":"427","author":"TG Keys","year":"2012","unstructured":"Keys, T. G., Berger, M. & Gerardy-Schahn, R. A high-throughput screen for polysialyltransferase activity. Anal. Biochem. 427, 60\u201368 (2012).","journal-title":"Anal. Biochem."},{"key":"BFnpjvaccines201617_CR41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nchembio.1501","volume":"10","author":"TG Keys","year":"2014","unstructured":"Keys, T. G. et al. Engineering the product profile of a polysialyltransferase. Nat. Chem. Biol. 10, 437\u2013442 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"BFnpjvaccines201617_CR42","doi-asserted-by":"publisher","first-page":"11718","DOI":"10.1074\/jbc.M113.452276","volume":"288","author":"A Romanow","year":"2013","unstructured":"Romanow, A. et al. Biochemical and biophysical characterization of the sialyl-\/hexosyltransferase synthesizing the meningococcal serogroup W135 heteropolysaccharide capsule. J. Biol. Chem. 288, 11718\u201311730 (2013).","journal-title":"J. Biol. Chem."},{"key":"BFnpjvaccines201617_CR43","doi-asserted-by":"publisher","first-page":"33945","DOI":"10.1074\/jbc.M114.597773","volume":"289","author":"A Romanow","year":"2014","unstructured":"Romanow, A. et al. Dissection of hexosyl- and sialyltransferase domains in the bifunctional capsule polymerases from Neisseria meningitidis W and Y defines a new sialyltransferase family. J. Biol. Chem. 289, 33945\u201333957 (2014).","journal-title":"J. Biol. Chem."},{"key":"BFnpjvaccines201617_CR44","doi-asserted-by":"publisher","first-page":"24355","DOI":"10.1074\/jbc.M115.678094","volume":"290","author":"C Litschko","year":"2015","unstructured":"Litschko, C. et al. The capsule polymerase CslB of Neisseria meningitidis serogroup L catalyzes the synthesis of a complex trimeric repeating unit comprising glycosidic and phosphodiester linkages. J. Biol. Chem. 290, 24355\u201324366 (2015).","journal-title":"J. Biol. Chem."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/npjvaccines201617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npjvaccines201617","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npjvaccines201617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T12:35:44Z","timestamp":1672835744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npjvaccines201617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,1]]}},"alternative-id":["BFnpjvaccines201617"],"URL":"https:\/\/doi.org\/10.1038\/npjvaccines.2016.17","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,15]]},"assertion":[{"value":"10 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors MRR, DO, RA, MT, BB, LS, PC and FB are full-time employees of GSK Vaccines. The authors TF, MB and RG-S have submitted patent applications for glycoconjugate vaccines against <i>Nm<\/i>X.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16017"}}